Protagen applies its automated screening platform technology, SeroTag®, for the detection of autoantibody signatures in patient serum to detect novel, disease-specific biomarkers for better patient profiling and response prediction within the two main therapeutic areas; immuno-oncology and autoimmune disease.
Protagen supports effective immunotherapy development via SeroTag®. By profiling patient autoantibodies, Protagen provides a better understanding of the response rates of cancer-immunotherapies and supports the early detection, monitoring and management of irAEs.
Patient stratification - NavigAID
Protagen’s NavigAID portfolio of patient stratification arrays enable the classification of different patient subgroups for better disease activity assessment and improved response prediction; for indications such as SSc, SLE, RA, SjS and others.
Protagen has focused on the identification of novel, proprietary biomarkers for SSC the first of which, BICD2, is now available as a CE-Mark assay and adds to our IVD portfolio of SCL70 and CENP-B, two standard markers used in the diagnosis of SSc.
Protagen specializes in Pharma development services, novel diagnostics and companion diagnostics, in the field of immuno-oncology and autoimmune disease. Using its proprietary SeroTag® biomarker discovery platform and its portfolio of NavigAID patient stratification products, Protagen identifies valuable biomarkers that support pharmaceutical development and personalized treatment with targeted therapies. Utilizing pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies.
Autoimmune and Immuno-oncology
The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. Protagen’s SeroTag® technology has been applied for the development of the NavigAID portfolio of patient stratification arrays for autoimmune indications such as SSc. SLE, RA and SJS. Protagen also aims to develop NavigAID for immuno-oncology application. Here it enables differential diagnosis, better disease activity assessment and improved response prediction. Protagen’s SeroTag® technology is also being applied to the field of immuno-oncology where it is helping pharmaceutical and biotech companies to address, identify and monitor a number of issues currently hindering the successful development and broader application of certain cancer immunotherapies, such as low response rates and immune related adverse events (irAEs) and the onset of autoimmune disease.